264 related articles for article (PubMed ID: 1834291)
1. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
BMJ; 1991 Oct; 303(6807):884-93. PubMed ID: 1834291
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
Williams CJ; Stewart L; Parmar M; Guthrie D
Semin Oncol; 1992 Feb; 19(1 Suppl 2):120-8. PubMed ID: 1411623
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
Stewart L;
Cochrane Database Syst Rev; 2000; (2):CD001418. PubMed ID: 10796788
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.
Aabo K; Adams M; Adnitt P; Alberts DS; Athanazziou A; Barley V; Bell DR; Bianchi U; Bolis G; Brady MF; Brodovsky HS; Bruckner H; Buyse M; Canetta R; Chylak V; Cohen CJ; Colombo N; Conte PF; Crowther D; Edmonson JH; Gennatas C; Gilbey E; Gore M; Guthrie D; Yeap BY
Br J Cancer; 1998 Dec; 78(11):1479-87. PubMed ID: 9836481
[TBL] [Abstract][Full Text] [Related]
5. The results of a quantitative overview of chemotherapy in advanced ovarian cancer: what can we learn?
Stewart LA; Parmar MK
Bull Cancer; 1993 Feb; 80(2):146-51. PubMed ID: 8173166
[TBL] [Abstract][Full Text] [Related]
6. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
8. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
11. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
12. Options for primary chemotherapy in advanced ovarian cancer: the European perspective.
Colombo N; Maggioni A; Vignali M; Parma G; Mangioni C
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S108-13. PubMed ID: 7835793
[TBL] [Abstract][Full Text] [Related]
13. Advanced ovarian cancer. Carboplatin versus cisplatin.
Vermorken JB; ten Bokkel Huinink WW; Eisenhauer EA; Favalli G; Belpomme D; Conte PF; Kaye SB
Ann Oncol; 1993; 4 Suppl 4():41-8. PubMed ID: 8312200
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
[TBL] [Abstract][Full Text] [Related]
15. [Carboplatin in cancer of the ovary].
Pujade-Lauraine E; Guastalla JP; Vincent P
Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
[TBL] [Abstract][Full Text] [Related]
16. [Recent advances in ovarian cancer chemotherapy from the survival standpoint].
Hatae M; Onishi Y; Maeda Y; Maeda T; Hirano T; Kamitomo M
Gan To Kagaku Ryoho; 1995 May; 22(6):718-25. PubMed ID: 7755379
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
18. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
19. Platinum alone for chemotherapy for ovarian cancer?
Johnston C
Lancet; 1998 Nov; 352(9140):1567-8. PubMed ID: 9843097
[No Abstract] [Full Text] [Related]
20. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
Cure H; Dauplat J; Cholet P
Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
